Compare CSX Corporation (CSX) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Enveric Biosciences Inc — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: CSX Corporation is far larger — about 12897.1× Enveric Biosciences Inc's market cap, and CSX Corporation pays a 1.18% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Enveric Biosciences Inc for 14 Days on average.
| CSX | ENVB | |
|---|---|---|
Market Cap | $87.70B | $6.80M |
Volume | 6,980,781 | 64,867 |
Sector | Industrials | Health |
52-Week High | $53.21 | $10.80 |
52-Week Low | $33.68 | $1.27 |
Typical Hold Time | 55 Days | 14 Days |
Enterprise Value | $105.66B | -$1.49M |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% with a bearish technical signal. The railroad operator shows mixed fundamentals with declining revenue from $14.9B in 2022 to $14.1B in 2025, though net income margins remain strong at 22.21%. Recent earnings show two beats and one miss, with Q3 2026 results pending. Analyst consensus is bullish with 59% buy ratings and a $51 price target, representing 9% upside from current levels.
CSX offers steady dividend income and pricing power in an irreplaceable freight network, but faces revenue pressure and elevated valuation multiples. The stock's investment case hinges on operational efficiency gains and freight volume recovery, balanced against economic sensitivity and competitive pressures in the transportation sector.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
